CINECA IRIS Institutional Research Information System

GABBIANI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.112
EU - Europa 3.246
AS - Asia 1.257
AF - Africa 175
SA - Sud America 17
OC - Oceania 10
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.819
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.917
IT - Italia 1.327
SE - Svezia 763
CN - Cina 596
BG - Bulgaria 317
SG - Singapore 310
DE - Germania 197
CA - Canada 193
VN - Vietnam 150
UA - Ucraina 149
SN - Senegal 112
FI - Finlandia 105
GB - Regno Unito 104
TR - Turchia 97
CH - Svizzera 85
CI - Costa d'Avorio 55
HK - Hong Kong 50
RU - Federazione Russa 41
EE - Estonia 32
AT - Austria 31
IN - India 26
FR - Francia 20
BE - Belgio 14
GR - Grecia 14
ES - Italia 12
PL - Polonia 11
BR - Brasile 10
AU - Australia 7
IE - Irlanda 6
BJ - Benin 5
CZ - Repubblica Ceca 5
JP - Giappone 5
NL - Olanda 5
IR - Iran 4
NZ - Nuova Zelanda 3
PK - Pakistan 3
TW - Taiwan 3
AR - Argentina 2
IQ - Iraq 2
KR - Corea 2
LI - Liechtenstein 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BS - Bahamas 1
CL - Cile 1
CO - Colombia 1
CU - Cuba 1
DK - Danimarca 1
EU - Europa 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
OM - Oman 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 13.819
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.615
Fairfield 1.142
Houston 930
Ann Arbor 925
Ashburn 595
Milan 481
Seattle 477
Chandler 464
Cambridge 408
Wilmington 375
Sofia 317
Serra 287
Jacksonville 252
Ottawa 183
Beijing 174
New York 174
Boardman 140
Princeton 136
Nanjing 130
Lawrence 115
Dakar 112
Medford 112
Izmir 96
Singapore 90
Bern 85
Jüchen 61
Abidjan 55
Dearborn 55
San Diego 52
Hong Kong 48
Des Moines 47
Dong Ket 46
Nanchang 40
Boulder 39
Rome 39
Florence 35
Tallinn 32
Vienna 28
Fuzhou 26
Pisa 26
Ogden 25
Livorno 24
Hebei 23
Shenyang 22
Falls Church 21
Changsha 19
Redwood City 18
Bremen 17
Kunming 17
London 17
Shanghai 17
Pune 15
Brussels 14
Hefei 13
Jiaxing 13
Norwalk 13
Tianjin 13
Los Angeles 12
Quanzhou 12
Padova 11
Vicopisano 11
Trento 10
Kent 9
Fabriano 8
Frankfurt am Main 8
Prato 8
San Giuliano Terme 8
Hangzhou 7
Auburn Hills 6
Changchun 6
Giussano 6
Guangzhou 6
Torino 6
Washington 6
Burgos 5
Cotonou 5
Edinburgh 5
Lubin 5
Sassari 5
Wuhan 5
Council Bluffs 4
Helsinki 4
Jinan 4
Lucca 4
Marseille 4
Noli 4
Sesto Fiorentino 4
Siracusa 4
São Paulo 4
Tokyo 4
Warsaw 4
Amherst 3
Atessa 3
Chicago 3
Chieti 3
Chiswick 3
Detroit 3
Dublin 3
Durham 3
Graz 3
Totale 10.986
Salva come PNG Salva come JPEG
Nome #
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 192
Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities 190
New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen 188
Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: The binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin 187
ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes 169
The reaction of artemisinins with hemoglobin: A unified picture 164
Gold(III) Compounds as anticancer drugs 163
Unravelling the Chemical Nature of Copper Cuprizone 157
Peculiar Mechanistic and Structural Features of the Carboplatin-Cytochrome c System Revealed by ESI MS analysis 155
X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins 155
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation 154
Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c 153
The C2 variant of human serum transferrin retains the iron binding properties of the native protein 152
Antitumor gold(III) complexes 148
Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound 148
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study 148
Arene Ruthenium Complexes with Ethacrynic Acid-Modified Ligands: Synthesis, Characterization and Antiproliferative Activity 146
Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands 145
PtI2(DACH), the Iodido Analogue of Oxaliplatin as a Candidate for Colorectal Cancer Treatment: Chemical and Biological Features 145
Interaction of gold N-heterocyclic carbenes with nucleic acids 145
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 144
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme 144
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs 144
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications 141
Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds 141
DOTAP/DOPE and DC-Chol/DOPE Lipoplexes for Gene Delivery studied by Circular Dichroism and Biophysical Techniques 138
Solution chemistry and cytotoxic properties of novel organogold(III) compounds 137
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 137
Metal compounds as inhibitors of B-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer’s disease 137
Proanthocyanidin glycosides from the leaves of Quercus ilex L. (Fagaceae) 136
Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity 136
The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif 136
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study 136
Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme 135
Nanoparticles of Mg(OH)2: Synthesis and Application to Paper Conservation 134
Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs 133
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 133
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments 133
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis 132
Photocytotoxic Pt(iv) complexes as prospective anticancer agents 132
Metal-based compounds as prospective antileishmanial agents: Inhibition of Trypanothione reductase by selected gold complexes 131
Synthesis and Antiproliferative Activity of New Ruthenium Complexes with Ethacrynic Acid-Modified Ligands 131
Solution Behaviour and Biomolecular Interactions of Two Cytotoxic trans-Platinum(II) Complexes Bearing Aliphatic Amine Ligands 130
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound 130
Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials 128
cis-Pt I2(NH3)2: a reappraisal 127
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study 125
Interaction of a Gold(I) Dicarbene Anticancer Drug with Human Telomeric DNA G-Quadruplex: Solution and Computationally Aided X-ray Diffraction Analysis 125
The copper(II) binding properties of the cyclic peptide c(HGHK) 122
Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells 121
Structure-Function Relationships within Keppler-Type Antitumor Ruthenium(III) Complexes: the Case of 2-Aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)] 120
The influence of auranofin, a clinically established antiarthritic gold drug, on bone metabolism: analysis of its effects on human multipotent adipose-derived stem cells, taken as a model 120
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 120
Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives 119
Anticancer gold N-Heterocyclic carbene complexes: a comparative in vitro and ex vivo study 118
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 117
Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro 117
Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action 116
Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(III) compounds studied with combined mass spectrometry and biochemical assays 114
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones 113
Novel platinum(II) compounds with O,S bidentate ligands: Synthesis, characterization, antiproliferative properties and biomolecular interactions 113
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles 113
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 112
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. 111
Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins 110
Aluminum, copper, iron and zinc differentially alter amyloid-Abeta(1-42) aggregation and toxicity 109
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand 109
Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. 108
Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex 108
New insights into the molecular mechanisms of selected anticancer metal compounds through bioinformatic analysis of proteomic data 108
New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro 108
Reactivity and Biological Properties of a Series of Cytotoxic PtI(2)(amine)(2) Complexes, Either cis or trans Configured 108
Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents 107
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds 107
Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties 107
The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins 106
Trans-cis-cis-[RuCl(2)(DMSO)(2)(2-amino-5-methyl-thiazole)(2)], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B 106
The mode of action of anticancer gold-based drugs: A structural perspective 106
Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c 106
Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. 106
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc 103
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles 103
Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation 103
Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial "hot spots" for protein-protein recognition 102
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 100
Biophysical Characterization of Adducts Formed between Anticancer Metallodrugs and Selected Proteins: New Insights from X-ray Diffraction and Mass Spectrometry Studies 99
Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c 99
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 99
Dinuclear Gold(III) Complexes as Potential Anticancer Agents: Structure, Reactivity and Biological Profile of a Series of Gold(III) Oxo-Bridged Derivatives 97
Proteomic analysis of the cytotoxic effects induced by the organogold(iii) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 97
[Au2(phen2Me)2(µ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties 96
Recent progress in the application of analytical techniques to anticancer metallodrug proteomics 96
Proteins as possible targets for antitumor metal complexes: biophysical studies of their interactions 93
Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid-beta(1-42): An AFM Study 93
Triethylphosphine gold iodide (I), the iodido analogue of Auranofin: comparative studies of a potential antineoplastic agent 93
Ruthenium arene complexes with triphenylphosphane ligands: Cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution 93
Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability 90
Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for the mechanism of action 88
Protein Targets for Anticancer Gold Compounds: Mechanistic Inferences 86
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents 85
Totale 12.470
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.847
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.847
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.919 0 0 0 197 267 295 287 211 298 147 179 38
2020/20211.477 127 54 85 67 77 64 79 316 188 162 68 190
2021/20221.541 17 88 169 129 263 165 62 90 62 13 139 344
2022/20231.836 272 218 132 137 147 237 47 155 363 23 78 27
2023/20241.666 239 198 282 119 272 278 55 32 27 20 46 98
2024/2025323 1 134 25 163 0 0 0 0 0 0 0 0
Totale 14.109